Harpoon has developed a portfolio of novel T-cell engagers and proprietary platforms that deliver engineered proteins to direct a patient’s own immune cells to kill tumors. The company also has additional cancer drugs in early clinical trials, according to a Jan. 8 Merck news release.
The acquisition is expected to be completed in the first half of 2024.
Commonly prescribed medications such as statins, non-steroidal anti-inflammatory drugs and certain blood pressure drugs may significantly delay the onset of…
In recent weeks, biotech companies have faced setbacks in moving forward with clinical trials due to operational delays at the…
Arkansas has become the first state to ban pharmacy benefit managers from owning pharmacies after Gov. Sarah Huckabee Sanders signed…
Comments are closed.
